I did a lot of reading about DOR over the weekend and I used sites that were not DOR PR info, sites like small cap investments, ect. And this is what I found, sorry I have no links because I did this research at work and can not copy and paste there. However all this info can be found by doing a Google search. This basically has to do with the delisting issue.
1. Orbec NDA will not help us. Investors already know we are going to file it and they stated that it will be "by the end of the year" Not soon enough
2. Rivax final results won't be until FEB! I read that it will take one full year to get all the results, that won't be until Feb more than likely later than that.
3. BT-VACC, this may work by getting us some more govt grant money that will increase our SHE (lets hope)
4. Reverse split with offering, just not enough time to vote on and execute IMO
5. Financial parter of some sort, I doubt it but maybe
So in my opinion we may just get delisted, which isn't the end of the world. Long term there still is lots of potential GLA
"The application includes a revised label and risk management plan and a safety assessment of patients treated with Tysabri in clinical trials, among other data. The companies have also requested priority review status for the application, which, if granted, would result in action by the FDA about six months from the submission date, rather than 10 months for a standard review. "
this is AFTER they already went through a regular review... its ANOTHER 6 months instead of 10, NOT total.
ELAN is a stock I know well and follow
Fast Track can be 6 months. See below on ELN
Market Pulse: Biogen, Elan file supplemental Tysabri application for MS
Monday September 26, 4:23 pm ET
By Carla Mozee
SAN FRANCISCO (MarketWatch) -- Biogen Idec Inc. and Elan Corp. Plc said after Monday's closing bell that they have submitted a supplemental biologics license application to the Food and Drug Administration for Tysabri for the treatment of multiple sclerosis. The application includes a revised label and risk management plan and a safety assessment of patients treated with Tysabri in clinical trials, among other data. The companies have also requested priority review status for the application, which, if granted, would result in action by the FDA about six months from the submission date, rather than 10 months for a standard review.
Yes...full results in Feb for EIVAX..but, we should get Phase 1 results this month. They hinted to it in their last PR, without being date specific. They released pre-lim phase 1 in July, if I remeber and were confident in them. Phase 1 is very important for RIVAX (RICIN vac.) it's the SAFETY study, which is critrical JMHO.
Your post is no knowledge as all about DOR. Did you base on "Liar Liar" standard... You just try to make investor confuse...That's a stupid thing to do... No one stupid than U.
"..They hinted .." How do you know ?
DOR will go DOWN more because No juicy for Finance.
I don't think delisting matters much. There are plenty of good stocks on the BB. The real issue is when and how they are going get their next financing. If it is like the last pipe, watch out for that selling pressure again, it could be the time to buy.
Question: Does fast track mean 6 month decision from the FDA or NOT?